Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Itsatrapon Apr 11, 2018 10:14pm

163 Views

Post# 27870805

RE:RE:RE:Any ideas

You might be right Pandora, the release itself doesn't specify but Business Wire titled this news as an "executive search". https://www.businesswire.com/news/home/20180411006413/en/Antibe-Therapeutics-Engages-Blaise-Group-International-Executive ------- My post may have been merely wishful thinking. (Pardon my horrid formatting.)

Pandora wrote:
gimmycash wrote: its not very clear it could be patients for the trials or staff.but either way something is getting done.so its all good.

".... a leading healthcare-focused executive recruitment agency, to augment its global business development expertise."

Sounds like they are head hunting for an executive -- or more than one -- for an area off shore.